Healthcare stocks were broadly higher with the NYSE Healthcare
Sector Index rising about 0.9% and shares of healthcare companies
in the S&P 500 adding about 1.1% as a group.
In company news, NewLink Genetics (
) shares surged as much as 21% today after the biotech company said
it is ready to begin testing its prospective Ebola vaccine in
"We're getting a lot of assistance from a number of sources to
accelerate this," according to Gordon Link, chief financial officer
at the company, later adding "people are greasing the paths as much
as they can," making it difficult to come up with a precise
schedule for the start of testing.
The VSV-EBOV vaccine was developed by Canada's National
Microbiology Laboratory and is licensed by NLNK, which has been
working "around the clock" to start trials, president Nicholas
Vahanian today told Bloomberg News in a telephone interview.
NLNK shares were up over 10% at $24.82 each shortly before the
closing bell Thursday afternoon, earlier climbing to a session high
of $28.30 a share. The stock has traded within a 52-week range of
$15.61 to $53.48 a share, rising about 33.3% over the past 12
In other sector news,
(+) MDRX, Extends partnership with Clinical Architecture,
integrating its dbMotion health information exchange with
Clinical's Symedical terminology management system and providing
more efficient mapping tool and vocabularies distribution.
(-) CNAT, Postpones release of Phase II testing of emricasan
drug candidate in patients with nonalcoholic fatty liver disease
until Q1 of 2015 from late 2014. Q2 net loss of $5.3 mln, or $0.34
per share, beats analyst estimates by $0.05 per share.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.